Amruth Palla, MD
Hematology · Midland, MINPI 1922205681
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.0% of the total across 14 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Tempus AI, Inc at 30.9% of the total. Reporting peaked in 2019 at $382 and has fallen 51.9% since, to $184 in 2025. That places this record below the midpoint for hematology clinicians in MI, where the typical reported total is $667.
Across 14 payments — averaging $47.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tempus AI, Inc$204
- Johnson & Johnson$168
- Genentech USA, Inc.$93
- Novartis$79
- Pharmacyclics LLC, An Abbvie Company$55
- Janssen Scientific Affairs, LLC$31
- plus $32 from 2 others
What the payments were for
- Food & beverage$64297%
- Education$203%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tempus AI, Inc | 3 | $204 |
| Johnson & Johnson(2 entities) | 2 | $168 |
| Genentech USA, Inc. | 3 | $93 |
| Novartis | 1 | $79 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $55 |
| Janssen Scientific Affairs, LLC | 2 | $31 |
| Merck | 1 | $20 |
| Pfizer | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$661 in reported general payments places this provider in the 45th percentile of 50 hematology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 25 | $395,714 |
| BrukinsaZanubrutinib | 23 | $330,955 |
| Lenalidomide | 17 | $269,903 |
| InlytaAxitinib | 13 | $265,447 |
| XtandiEnzalutamide | 13 | $191,912 |
| VenclextaVenetoclax | 17 | $190,090 |
| IbrancePalbociclib | 11 | $178,928 |
| CabometyxCabozantinib S-Malate | 13 | $174,716 |
| Abiraterone Acetate | 34 | $65,575 |
| AranespDarbepoetin Alfa In Polysorbat | 28 | $51,172 |
| OrgovyxRelugolix | 12 | $32,537 |
| EliquisApixaban | 43 | $30,825 |
| XareltoRivaroxaban | 16 | $21,923 |
| Anastrozole | 379 | $14,849 |
| Exemestane | 23 | $5,942 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerInlyta, Ibrance, Eliquis | $12 | $475,20067 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $55 | $395,71425 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $31 | $65,57534 claims |
| Johnson & JohnsonXarelto | $168 | $21,92316 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 50 hematology providers in Michigan.
Other hematology in Midland
- Craig ColeLansing$159K
- Ahmad MattourDetroit$56K
- Matthew PiankoAnn Arbor$51K
- Sami MalekAnn Arbor$49K
- Yasmin KarimiAnn Arbor$47K
- Kristen PettitAnn Arbor$45K
- Samuel SilverAnn Arbor$23K
- Asif AlaviDetroit$17K
- Jordan SchaeferAnn Arbor$14K
- Paul SwerdlowDetroit$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.